Skip to main content
. 2021 Jan 20;20:508–519. doi: 10.1016/j.omtm.2021.01.006

Figure 4.

Figure 4

Virally expressed MCT1 is still detectable at disease end-stage in ALS mice

(A) Double immunostaining for the oligodendrocyte marker CC1 (red) and the Myc tag (green) or GFP shows the presence of vector expressed MCT1 and GFP in spinal cord oligodendrocytes (upper and middle panel), while MBP-Empty-AAV-injected mice show no Myc or GFP immunoreactivity (lower panel). Scale bar, 50 μm. Right column represents a magnification of the left side images. Scale bar, 20 μm. (B) qPCR analysis of spinal cord lysates from MBP-MCT1FLAG/Myc-AAV9-injected mice shows upregulation of total MCT1 mRNA expression at end-stage disease. Data are presented as mean ± SEM, n = 4-9 mice per group, one-way ANOVA ∗∗∗p < 0.001. (C) Dot blot analysis of FLAG-tagged MCT1 protein levels in brain lysates. Ponceau staining was used as a loading control. EMPTY, MBP-Empty-AAV9-injected; GFP, MBP-GFP-AAV9-injected; MCT1, MBP-MCT1FLAG/Myc-AAV9-injected.